Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan.
Ya-Ting HsuShang-Ju WuHsiao-Wen KaoSheng-Yen HsiaoChun-Kai LiaoTsai-Yun ChenMing-Chung WangPublished in: Cancer (2024)
In this real-world cohort, glofitamab exhibited effectiveness comparable to trial results without excessive CRS or new safety issues. With appropriate prophylaxis, glofitamab-treated patients with chronic or remote HBV infection are unlikely to experience virus reactivation.